Funding
Cancer
CANCER
The CAP trial is funded by Cancer Research UK/UK Department of Health (C11043/A4286, C18281/A8145, C18281/A11326, C18281/A15064 and C18281/A24432). The ProtecT trial is funded by the UK National Institute for Health Research (NIHR) Health Technology Assessment Programme (projects 96/20/06, 96/20/99) with the University of Oxford (Oxford, UK) as sponsor. RMM was supported by a Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). All authors had financial support from Cancer Research UK and the UK Department of Health. RMM was supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. RMM, FCH, DEN and JLD are NIHR Senior Investigators. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The authors declare no financial relationships with any organisations that might have an interest in the submitted work in the previous three years and no other relationships or activities that could appear to have influenced the submitted work. External research grants administered by the Universities are listed above.